Every 10-Q that Wellgistics Health Inc. (WGRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow WGRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGRX filings page.
Wellgistics Health, Inc. reported very weak first-quarter 2026 results, highlighting serious financial strain and Nasdaq listing risks. Net revenues fell to $1.56 million from $10.86 million a year earlier, reflecting a sharp drop in distribution product revenue partly offset by higher pharmacy and logistics sales.
The company posted a net loss of $7.74 million, though this was smaller than the prior-year loss of $32.43 million, and generated a gross profit of only $170,221. Operating expenses were $6.19 million, and net interest expense remained heavy.
As of March 31, 2026, Wellgistics held just $51,730 of cash against $45.19 million of liabilities and a stockholders’ deficit of $15.06 million, prompting management and auditors to state that there is substantial doubt about its ability to continue as a going concern.
During the quarter the company raised $6.5 million of cash through secured convertible notes with an $8.13 million face amount and issued significant equity and warrants to settle compensation and vendor obligations, further diluting shareholders.
Wellgistics also received Nasdaq deficiency notices for failing the $1.00 minimum bid price and the $2.5 million minimum stockholders’ equity requirements. Management is pursuing additional financing, a potential reverse stock split, a new collaboration venture, and proxy proposals to adjust its capital structure, but outcomes remain uncertain.
Wellgistics Health, Inc. (WGRX) reported sharp losses and liquidity pressures in its quarter ended September 30, 2025. Net revenues rose to $21.7 million for the nine months, primarily from product distribution, pharmacy retail sales, and third-party logistics, but were outweighed by operating expenses of $69.8 million, including $54.4 million of stock-based compensation. The company posted a nine‑month net loss of $73.4 million versus $2.5 million a year earlier and ended the period with $4.2 million in cash and total debt of $24.8 million.
Management concluded that these losses, negative operating cash flow, and high leverage raise substantial doubt about the company’s ability to continue as a going concern without additional capital. To bolster liquidity, Wellgistics completed a February 2025 IPO raising about $3.1 million net, used an equity purchase agreement to raise $2.8 million, and in September 2025 sold 7,142,862 shares with matching warrants for net proceeds of $4.5 million, followed by warrant exercises that brought in another $2.2 million.
Wellgistics Health, Inc. reported significant operating losses and liquidity strain for the period ending June 30, 2025. The company recorded a net loss of $39.1 million for the six months and $6.67 million for the three months, contributing to an accumulated deficit of $48.86 million. Net cash used in operating activities for the six months was $3.43 million, and the registrant disclosed that these factors raise substantial doubt about its ability to continue as a going concern. The company completed an IPO raising gross proceeds of $4.0 million (net approx. $3.1 million) and issued shares under an equity purchase agreement that was subsequently terminated on August 13, 2025. Debt and credit facilities remain significant, including a revolving line of credit balance of $3.98 million and seller notes with $5.0 million classified as current. Intangible assets and goodwill are material on the balance sheet (~$19.2 million and $16.2 million, respectively). The filing also discloses a customer concentration risk (~15% of revenue) and elevated stock-based compensation and restricted-share programs.